Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219799 · ClinicalTrials.gov registry record · Early Phase 1
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
A Early Phase 1 study of Healthy and Obesity, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05219799 is a Early Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 72 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05219799, a Early Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.
Conditions Studied
Interventions
- DRUG Norepinephrine
- DRUG Isoproterenol
- DRUG Propranolol Hydrochloride
- DRUG Phentolamine Mesylate
Study Locations (1)
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2026-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05219799
The ClinicalTrials.gov registry entry for NCT05219799 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Norepinephrine is the first listed.
NCT05219799 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05219799 about?
NCT05219799 is a clinical study titled "Sex Disparities in Hypoxic Vasodilation and Impact of Obesity". The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.
What is the current status of trial NCT05219799?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2023-03-14. Estimated completion is 2026-06-30.
What conditions does trial NCT05219799 study?
This clinical trial studies the following conditions: Healthy, Obesity, Vasodilation.
What interventions are being tested in trial NCT05219799?
The interventions under investigation include: Norepinephrine (DRUG), Isoproterenol (DRUG), Propranolol Hydrochloride (DRUG), Phentolamine Mesylate (DRUG).
Who is sponsoring clinical trial NCT05219799?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05219799 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
-
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.